Frazier Lifesciences Acquisition Corporation
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.55 EUR | -8.62% |
|
+3.20% | +81.74% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+81.74% | 1.83B | |
+15.58% | 122B | |
+16.60% | 113B | |
+17.55% | 26.22B | |
-24.33% | 19.01B | |
-19.14% | 15.71B | |
-17.95% | 15.22B | |
-46.81% | 14.72B | |
+58.78% | 14.58B | |
+4.91% | 13.84B |
- Stock Market
- Equities
- NAMS Stock
- News Frazier Lifesciences Acquisition Corporation
- NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043